Kiniksa Pharmaceuticals International (KNSA) Accumulated Depreciation & Amortization (2021 - 2025)
Kiniksa Pharmaceuticals International (KNSA) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $7.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 11.75% year-over-year to $7.2 million, compared with a TTM value of $7.2 million through Dec 2025, down 11.75%, and an annual FY2025 reading of $7.2 million, down 11.75% over the prior year.
- Accumulated Depreciation & Amortization was $7.2 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $7.8 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $8.2 million in Q4 2024 and bottomed at $5.0 million in Q1 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $7.2 million, with a median of $7.4 million recorded in 2023.
- The sharpest move saw Accumulated Depreciation & Amortization rose 15.96% in 2022, then dropped 11.75% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $5.9 million in 2021, then grew by 15.96% to $6.9 million in 2022, then increased by 13.5% to $7.8 million in 2023, then grew by 5.24% to $8.2 million in 2024, then decreased by 11.75% to $7.2 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for KNSA at $7.2 million in Q4 2025, $7.8 million in Q3 2025, and $8.2 million in Q4 2024.